HoPE (Hospice Preparation and Education)

Hospice Care Clinical Trial

Official title:

Pilot Trial Evaluating Usability, Acceptability, and Feasibility of the HoPE (Hospice Preparation and Education) Web-Based Tool

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04410627
• Other study ID #: Pro00105058
• Status: Withdrawn
• Phase: N/A
• Start date: June 1, 2022
• Est. completion date: December 31, 2022

Study information

• Verified date: March 2022
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigator will conduct a two-site, randomized, controlled study of the HoPE (Hospice Preparation and Education) web-based tool versus usual care to assess: Technology usability (primary), study feasibility (secondary), user acceptability (secondary), and hospice service conversion rate (exploratory). Technology usability will be assessed through a one-time quantitative survey using established instruments. Study feasibility and user accessibility will be assessed through trial enrollment and retention alongside analytics assessing tool usage (e.g. time spent on each page of the website). Conversion rate is the percent of patients introduced to hospice who eventually enroll. The investigators will evaluate in an exploratory manner the differential effect of HoPE versus usual care.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 31, 2022
• Est. primary completion date: December 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 89 Years

Eligibility

Inclusion Criteria:

• Eligible for and referral made for home hospice services (Note: this excludes home palliative care, home infusion, home nursing, home physical therapy, and bridge services)

• Aged between 21 and 89

• Capacity to give consent

• Ability to speak and understand English

Related Conditions & MeSH terms

• Hospice Care

Intervention

Other:
• HoPE Website
Educational website focused on hospice care

Locations

Country	Name	City	State
United States	Duke University Medical Center	Durham	North Carolina
United States	WakeMed Health & Hospitals	Raleigh	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Duke University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Technology usability as measured by System Usability Scale	To determine usability, the System Usability Scale will be administered to each participant in the intervention arm. As described by usability.gov: "The participant's scores for each question are converted to a new number, added together and then multiplied by 2.5 to convert the original scores of 0-40 to 0-100. Though the scores are 0-100, these are not percentages and should be considered only in terms of their percentile ranking. Based on research, a SUS score above a 68 would be considered above average and anything below 68 is below average, however the best way to interpret your results involves "normalizing" the scores to produce a percentile ranking."	At study completion, up to 4 months.
Secondary	Study Feasibility as measured by enrollment efficiency	Enrollment efficiency will be measured by the percentage of patients approached who enroll in the study, with the goal of >50% enrollment.	At study completion, up to 4 months
Secondary	Study Feasibility as measured by intervention completion	Intervention completion will be measured by the percentage of participants on the intervention arm who complete at least 50% of the modules within the intervention website, with a goal of >50% of the participants.	At study completion, up to 4 months
Secondary	User Accessibility as measured by Net Promoter score	The Net Promoter scale is administered to participants in the intervention arm of the study only. This scale is an eleven-item likert scale assessing likelihood to recommend the intervention to a family member or friend. The percentage of participants who give a score of 0 through 6 is subtracted by the percentage of participants who give a score of 9 or 10 to give the overall Net Promoter score. This score is then compared to other scores of similar technologies.	At study completion, up to 4 months